News
AlloHeme test accurately predicts relapse post-allo-HSCT in AML and MDS, with a median lead time of 36 days. The ACROBAT study involved 287 patients, showing significant predictive value of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback